Conventional strategies such as angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-II-receptor blockers (ARBs) are renoprotective and reduce the risk of end-stage renal disease (ERSD)19. This evidence concerns the gene ACE and stage 5 chronic kidney disease.